메뉴 건너뛰기




Volumn 12, Issue 5, 2011, Pages 460-486

The role and impact of SNPs in pharmacogenomics and personalized medicine

Author keywords

Biomarker; Cytochrome P450; HLA; Personalized Medicine; Personalized Medicine Therapeutics; Pharmacogenomics; Single Nucleotide Polymorphism; Stratified Medicine

Indexed keywords

ACETYLSALICYLIC ACID; ATOMOXETINE; AZATHIOPRINE; BIOLOGICAL MARKER; CARBAMAZEPINE; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DONEPEZIL; ESLICARBAZEPINE ACETATE; EXARTA; FOSPHENYTOIN SODIUM; GLUCURONOSYLTRANSFERASE 1A1; HLA ANTIGEN; HLA DR ANTIGEN; IMIPRAMINE; INOSINATE DEHYDROGENASE; IRINOTECAN; LAMOTRIGINE; MERCAPTOPURINE; NILOTINIB; NORTRIPTYLINE; OXCARBAZEPINE; PAZOPANIB; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TETRABENAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

EID: 79955678101     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011795495268     Document Type: Article
Times cited : (52)

References (230)
  • 1
    • 79959524146 scopus 로고    scopus 로고
    • A haplotype map of the human genome
    • A haplotype map of the human genome. Nature, 2005, 437 (7063), 1299-320.
    • (2005) Nature , vol.437 , Issue.7063 , pp. 1299-320
  • 4
    • 84953723083 scopus 로고    scopus 로고
    • Pharmacogenomics and personalized medicine: Mapping of future value creation
    • Hu, S. X.; Foster, T.; Kieffaber, A. Pharmacogenomics and personalized medicine: mapping of future value creation. Biotechniques, 2005, 39 (10 Suppl), S1-6.
    • (2005) Biotechniques , vol.39 , Issue.10 SUPPL.
    • Hu, S.X.1    Foster, T.2    Kieffaber, A.3
  • 5
    • 77954827460 scopus 로고    scopus 로고
    • The path to personalized medicine
    • Hamburg, M. A.; Collins, F. S. The path to personalized medicine. N. Engl. J. Med., 2010, 363 (4), 301-304.
    • (2010) N. Engl. J. Med. , vol.363 , Issue.4 , pp. 301-304
    • Hamburg, M.A.1    Collins, F.S.2
  • 6
    • 0035169803 scopus 로고    scopus 로고
    • Revealing the shared inheritance of all humankind
    • The Human Genome Project
    • Collins, F. S.; Mansoura, M. K. The Human Genome Project. Revealing the shared inheritance of all humankind. Cancer, 2001, 91 (1 Suppl), 221-225.
    • (2001) Cancer , vol.91 , Issue.1 SUPPL. , pp. 221-225
    • Collins, F.S.1    Mansoura, M.K.2
  • 8
    • 0037432755 scopus 로고    scopus 로고
    • The Human Genome Project: Lessons from large-scale biology
    • DOI 10.1126/science.1084564
    • Collins, F. S.; Morgan, M.; Patrinos, A. The Human Genome Project: lessons from large-scale biology. Science, 2003, 300 (5617), 286-290. (Pubitemid 36433711)
    • (2003) Science , vol.300 , Issue.5617 , pp. 286-290
    • Collins, F.S.1    Morgan, M.2    Patrinos, A.3
  • 10
    • 33947712686 scopus 로고    scopus 로고
    • Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers
    • DOI 10.1038/nrd2251, PII NRD2251
    • Trusheim, M. R.; Berndt, E. R.; Douglas, F. L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov., 2007, 6 (4), 287-293. (Pubitemid 46505879)
    • (2007) Nature Reviews Drug Discovery , vol.6 , Issue.4 , pp. 287-293
    • Trusheim, M.R.1    Berndt, E.R.2    Douglas, F.L.3
  • 11
    • 70349386728 scopus 로고    scopus 로고
    • Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part i
    • Zhou, S. F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet, 2009, 48 (11), 689-723.
    • (2009) Clin. Pharmacokinet , vol.48 , Issue.11 , pp. 689-723
    • Zhou, S.F.1
  • 12
    • 70449371633 scopus 로고    scopus 로고
    • Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II
    • Zhou, S. F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet, 2009, 48 (12), 761-804.
    • (2009) Clin. Pharmacokinet , vol.48 , Issue.12 , pp. 761-804
    • Zhou, S.F.1
  • 13
    • 78149470864 scopus 로고    scopus 로고
    • Polymorphisms of human cytochrome P450 2C9 and the functional relevance
    • Zhou, S. F.; Zhou, Z. W.; Huang, M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology, 2010, 278 (2), 165-188.
    • (2010) Toxicology , vol.278 , Issue.2 , pp. 165-188
    • Zhou, S.F.1    Zhou, Z.W.2    Huang, M.3
  • 14
    • 0036394942 scopus 로고    scopus 로고
    • Clinical significance of the cytochrome P450 2C19 genetic polymorphism
    • Desta, Z.; Zhao, X.; Shin, J. G.; Flockhart, D. A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet, 2002, 41 (12), 913-58. (Pubitemid 35168437)
    • (2002) Clinical Pharmacokinetics , vol.41 , Issue.12 , pp. 913-958
    • Desta, Z.1    Zhao, X.2    Shin, J.-G.3    Flockhart, D.A.4
  • 15
    • 65949112261 scopus 로고    scopus 로고
    • Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents
    • Garnock-Jones, K. P.; Keating, G. M. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr. Drugs, 2009, 11 (3), 203-26.
    • (2009) Paediatr. Drugs , vol.11 , Issue.3 , pp. 203-26
    • Garnock-Jones, K.P.1    Keating, G.M.2
  • 17
    • 3142519666 scopus 로고    scopus 로고
    • Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response
    • DOI 10.1038/sj.mp.4001494
    • Kirchheiner, J.; Nickchen, K.; Bauer, M.; Wong, M. L.; Licinio, J.; Roots, I.; Brockmoller, J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry, 2004, 9 (5), 442-473. (Pubitemid 38903502)
    • (2004) Molecular Psychiatry , vol.9 , Issue.5 , pp. 442-473
    • Kirchheiner, J.1    Nickchen, K.2    Bauer, M.3    Wong, M.-L.4    Licinio, J.5    Roots, I.6    Brockmoller, J.7
  • 18
    • 0031949132 scopus 로고    scopus 로고
    • 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes
    • DOI 10.1016/S0009-9236(98)90040-6
    • Dalen, P.; Dahl, M. L.; Bernal Ruiz, M. L.; Nordin, J.; Bertilsson, L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther., 1998, 63 (4), 444-452. (Pubitemid 28214968)
    • (1998) Clinical Pharmacology and Therapeutics , vol.63 , Issue.4 , pp. 444-452
    • Dalen, P.1    Dahl, M.-L.2    Ruiz, M.L.B.3    Nordin, J.4    Bertilsson, L.5
  • 19
    • 0029926315 scopus 로고    scopus 로고
    • Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: Relationship to the CYP2D6 genotype
    • DOI 10.1007/BF02246640
    • Dahl, M. L.; Bertilsson, L.; Nordin, C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl), 1996, 123 (4), 315-319. (Pubitemid 26075783)
    • (1996) Psychopharmacology , vol.123 , Issue.4 , pp. 315-319
    • Dahl, M.-L.1    Bertilsson, L.2    Nordin, C.3
  • 20
    • 0034115770 scopus 로고    scopus 로고
    • Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline
    • DOI 10.1097/00004714-200004000-00005
    • Morita, S.; Shimoda, K.; Someya, T.; Yoshimura, Y.; Kamijima, K.; Kato, N. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J. Clin. Psychopharmacol., 2000, 20 (2), 141-149. (Pubitemid 30202355)
    • (2000) Journal of Clinical Psychopharmacology , vol.20 , Issue.2 , pp. 141-149
    • Morita, S.1    Shimoda, K.2    Someya, T.3    Yoshimura, Y.4    Kamijima, K.5    Kato, N.6
  • 21
    • 12944281041 scopus 로고    scopus 로고
    • Amitriptyline or not, that is the question: Pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy
    • DOI 10.1373/clinchem.2004.041327
    • Steimer, W.; Zopf, K.; von Amelunxen, S.; Pfeiffer, H.; Bachofer, J.; Popp, J.; Messner, B.; Kissling, W.; Leucht, S. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem., 2005, 51 (2), 376-385. (Pubitemid 40175808)
    • (2005) Clinical Chemistry , vol.51 , Issue.2 , pp. 376-385
    • Steimer, W.1    Zopf, K.2    Von Amelunxen, S.3    Pfeiffer, H.4    Bachofer, J.5    Popp, J.6    Messner, B.7    Kissling, W.8    Leucht, S.9
  • 22
    • 0036204756 scopus 로고    scopus 로고
    • Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
    • DOI 10.1046/j.0306-5251.2001.01548.x
    • Bertilsson, L.; Dahl, M. L.; Dalen, P.; Al-Shurbaji, A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol., 2002, 53 (2), 111-122. (Pubitemid 34264265)
    • (2002) British Journal of Clinical Pharmacology , vol.53 , Issue.2 , pp. 111-122
    • Bertilsson, L.1    Dahl, M.-L.2    Dalen, P.3    Al-Shurbaji, A.4
  • 23
    • 0023032092 scopus 로고
    • Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype
    • Brosen, K.; Otton, S. V.; Gram, L. F. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther., 1986, 40 (5), 543-549. (Pubitemid 17185089)
    • (1986) Clinical Pharmacology and Therapeutics , vol.40 , Issue.5 , pp. 543-549
    • Brosen, K.1    Otton, S.V.2    Gram, L.F.3
  • 24
    • 0023139103 scopus 로고
    • Hydroxylation of desmethylimipramine: Dependence on the debrisoquin hydroxylation phenotype
    • Spina, E.; Steiner, E.; Ericsson, O.; Sjoqvist, F. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype. Clin. Pharmacol. Ther., 1987, 41 (3), 314-319. (Pubitemid 17034185)
    • (1987) Clinical Pharmacology and Therapeutics , vol.41 , Issue.3 , pp. 314-319
    • Spina, E.1    Steiner, E.2    Ericsson, O.3    Sjoqvist, F.4
  • 25
    • 0031028101 scopus 로고    scopus 로고
    • Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study
    • DOI 10.1007/s002280050220
    • Spina, E.; Gitto, C.; Avenoso, A.; Campo, G. M.; Caputi, A. P.; Perucca, E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur. J. Clin. Pharmacol., 1997, 51 (5), 395-398. (Pubitemid 27055908)
    • (1997) European Journal of Clinical Pharmacology , vol.51 , Issue.5 , pp. 395-398
    • Spina, E.1    Gitto, C.2    Avenoso, A.3    Campo, G.M.4    Caputi, A.P.5    Perucca, E.6
  • 26
    • 0025011753 scopus 로고
    • Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study
    • Sindrup, S. H.; Gram, L. F.; Skjold, T.; Grodum, E.; Brosen, K.; Beck-Nielsen, H. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind crossover study. Br. J. Clin. Pharmacol., 1990, 30 (5), 683-691. (Pubitemid 20377596)
    • (1990) British Journal of Clinical Pharmacology , vol.30 , Issue.5 , pp. 683-691
    • Sindrup, S.H.1    Gram, L.F.2    Skjold, T.3    Grodum, E.4    Brosen, K.5    Beck-Nielsen, H.6
  • 27
    • 0025076711 scopus 로고
    • Nonlinear kinetics of imipramine in low and medium plasma level ranges
    • Sindrup, S. H.; Brosen, K.; Gram, L. F. Nonlinear kinetics of imipramine in low and medium plasma level ranges. Ther. Drug Monit., 1990, 12 (5), 445-449. (Pubitemid 20314037)
    • (1990) Therapeutic Drug Monitoring , vol.12 , Issue.5 , pp. 445-449
    • Sindrup, S.H.1    Brosen, K.2    Gram, L.F.3
  • 29
    • 0036797601 scopus 로고    scopus 로고
    • Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers
    • DOI 10.1097/00008571-200210000-00010
    • Kirchheiner, J.; Meineke, I.; Muller, G.; Roots, I.; Brockmoller, J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics, 2002, 12 (7), 571-580. (Pubitemid 35177088)
    • (2002) Pharmacogenetics , vol.12 , Issue.7 , pp. 571-580
    • Kirchheiner, J.1    Meineke, I.2    Muller, G.3    Roots, I.4    Brockmoller, J.5
  • 31
    • 29544449443 scopus 로고    scopus 로고
    • Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19
    • DOI 10.1176/appi.psy.47.1.75
    • de Leon, J.; Armstrong, S. C.; Cozza, K. L. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics, 2006, 47 (1), 75-85. (Pubitemid 43017126)
    • (2006) Psychosomatics , vol.47 , Issue.1 , pp. 75-85
    • De Leon, J.1    Armstrong, S.C.2    Cozza, K.L.3
  • 35
    • 0026576928 scopus 로고
    • Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism
    • Sindrup, S. H.; Brosen, K.; Gram, L. F. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin. Pharmacol. Ther., 1992, 51 (3), 288-295.
    • (1992) Clin. Pharmacol. Ther , vol.51 , Issue.3 , pp. 288-295
    • Sindrup, S.H.1    Brosen, K.2    Gram, L.F.3
  • 36
    • 0032891488 scopus 로고    scopus 로고
    • The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine
    • Fjordside, L.; Jeppesen, U.; Eap, C. B.; Powell, K.; Baumann, P.; Brosen, K. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics, 1999, 9 (1), 55-60. (Pubitemid 29176724)
    • (1999) Pharmacogenetics , vol.9 , Issue.1 , pp. 55-60
    • Fjordsid, L.1    Jeppesen, U.2    Eap, C.B.3    Powell, K.4    Baumann, P.5    Brosen, K.6
  • 37
    • 0032849017 scopus 로고    scopus 로고
    • Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers [2]
    • DOI 10.1097/00004714-199910000-00014
    • Ozdemir, V.; Tyndale, R. F.; Reed, K.; Herrmann, N.; Sellers, E. M.; Kalow, W.; Naranjo, C. A. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. J. Clin. Psychopharmacol., 1999, 19 (5), 472-475. (Pubitemid 29451514)
    • (1999) Journal of Clinical Psychopharmacology , vol.19 , Issue.5 , pp. 472-475
    • Ozdemir, V.1    Tyndale, R.F.2    Reed, K.3    Herrmann, N.4    Sellers, E.M.5    Kalow, W.6    Naranjo, C.A.7
  • 38
    • 67650783189 scopus 로고    scopus 로고
    • Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions
    • Thomas, K. L.; Ellingrod, V. L. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy, 2009, 29 (7), 822-831.
    • (2009) Pharmacotherapy , vol.29 , Issue.7 , pp. 822-831
    • Thomas, K.L.1    Ellingrod, V.L.2
  • 39
    • 37349093041 scopus 로고    scopus 로고
    • Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors
    • Recommendations from the EGAPP Working Group
    • Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genetics in Medicine, 2007, 9 (12), 819-825.
    • (2007) Genetics in Medicine , vol.9 , Issue.12 , pp. 819-825
  • 41
    • 0032572599 scopus 로고    scopus 로고
    • Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics
    • DOI 10.1016/S0920-9964(98)00018-8, PII S0920996498000188
    • Ohmori, O.; Suzuki, T.; Kojima, H.; Shinkai, T.; Terao, T.; Mita, T.; Abe, K. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr. Res., 1998, 32 (2), 107-113. (Pubitemid 28364716)
    • (1998) Schizophrenia Research , vol.32 , Issue.2 , pp. 107-113
    • Ohmori, O.1    Suzuki, T.2    Kojima, H.3    Shinkai, T.4    Terao, T.5    Mita, T.6    Abe, K.7
  • 43
    • 2342562985 scopus 로고    scopus 로고
    • Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients
    • Liou, Y. J.; Wang, Y. C.; Bai, Y. M.; Lin, C. C.; Yu, S. C.; Liao, D. L.; Lin, M. W.; Chen, J. Y.; Lai, I. C. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology, 2004, 49 (4), 167-73.
    • (2004) Neuropsychobiology , vol.49 , Issue.4 , pp. 167-73
    • Liou, Y.J.1    Wang, Y.C.2    Bai, Y.M.3    Lin, C.C.4    Yu, S.C.5    Liao, D.L.6    Lin, M.W.7    Chen, J.Y.8    Lai, I.C.9
  • 46
    • 0036844154 scopus 로고    scopus 로고
    • Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6
    • Ellingrod, V. L.; Schultz, S. K.; Arndt, S. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy, 2002, 22 (11), 1416-1419. (Pubitemid 35266377)
    • (2002) Pharmacotherapy , vol.22 , Issue.11 , pp. 1416-1419
    • Ellingrod, V.L.1    Schultz, S.K.2    Arndt, S.3
  • 47
    • 17644423416 scopus 로고    scopus 로고
    • CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: A meta-analysis
    • Patsopoulos, N. A.; Ntzani, E. E.; Zintzaras, E.; Ioannidis, J. P. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet. Genomics, 2005, 15 (3), 151-158. (Pubitemid 40569901)
    • (2005) Pharmacogenetics and Genomics , vol.15 , Issue.3 , pp. 151-158
    • Patsopoulos, N.A.1    Ntzani, E.E.2    Zintzaras, E.3    Ioannidis, J.P.A.4
  • 48
    • 2642572803 scopus 로고    scopus 로고
    • Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1
    • DOI 10.1002/humu.20039
    • Neville, M. J.; Johnstone, E. C.; Walton, R. T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat., 2004, 23 (6), 540-545. (Pubitemid 38720604)
    • (2004) Human Mutation , vol.23 , Issue.6 , pp. 540-545
    • Neville, M.J.1    Johnstone, E.C.2    Walton, R.T.3
  • 49
    • 9844233161 scopus 로고    scopus 로고
    • D2 dopamine receptor gene (DRD2) Taq 1 A polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele
    • Thompson, J.; Thomas, N.; Singleton, A.; Piggott, M.; Lloyd, S.; Perry, E. K.; Morris, C. M.; Perry, R. H.; Ferrier, I. N.; Court, J. A. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics, 1997, 7 (6), 479-484. (Pubitemid 27517576)
    • (1997) Pharmacogenetics , vol.7 , Issue.6 , pp. 479-484
    • Thompson, J.1    Thomas, N.2    Singleton, A.3    Piggott, M.4    Lloyd, S.5    Perry, E.K.6    Morris, C.M.7    Perry, R.H.8    Ferrier, I.N.9    Court, J.A.10
  • 51
    • 0030598907 scopus 로고    scopus 로고
    • 3 receptor with the Semliki Forest virus system
    • DOI 10.1006/bbrc.1996.1296
    • Lundstrom, K.; Turpin, M. P. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem. Biophys. Res. Commun., 1996, 225 (3), 1068-1072. (Pubitemid 26319228)
    • (1996) Biochemical and Biophysical Research Communications , vol.225 , Issue.3 , pp. 1068-1072
    • Lundstrom, K.1    Turpin, M.P.2
  • 55
    • 0030975438 scopus 로고    scopus 로고
    • Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia
    • Chen, C. H.; Wei, F. C.; Koong, F. J.; Hsiao, K. J. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol. Psychiatry, 1997, 41 (7), 827-829.
    • (1997) Biol. Psychiatry , vol.41 , Issue.7 , pp. 827-829
    • Chen, C.H.1    Wei, F.C.2    Koong, F.J.3    Hsiao, K.J.4
  • 56
    • 33747441496 scopus 로고    scopus 로고
    • The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia
    • Liou, Y. J.; Lai, I. C.; Liao, D. L.; Chen, J. Y.; Lin, C. C.; Lin, C. Y.; Chen, C. M.; Bai, Y. M.; Chen, T. T.; Wang, Y. C. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr. Res., 2006, 86 (1-3), 323-325.
    • (2006) Schizophr. Res , vol.86 , Issue.1-3 , pp. 323-325
    • Liou, Y.J.1    Lai, I.C.2    Liao, D.L.3    Chen, J.Y.4    Lin, C.C.5    Lin, C.Y.6    Chen, C.M.7    Bai, Y.M.8    Chen, T.T.9    Wang, Y.C.10
  • 57
    • 36149001724 scopus 로고    scopus 로고
    • Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia
    • Mo, G. H.; Lai, I. C.; Wang, Y. C.; Chen, J. Y.; Lin, C. Y.; Chen, T. T.; Chen, M. L.; Liou, Y. J.; Liao, D. L.; Bai, Y. M.; Lin, C. C. Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia. Schizophr. Res., 2007, 97 (1-3), 302-304.
    • (2007) Schizophr. Res , vol.97 , Issue.1-3 , pp. 302-304
    • Mo, G.H.1    Lai, I.C.2    Wang, Y.C.3    Chen, J.Y.4    Lin, C.Y.5    Chen, T.T.6    Chen, M.L.7    Liou, Y.J.8    Liao, D.L.9    Bai, Y.M.10    Lin, C.C.11
  • 58
    • 34548317252 scopus 로고    scopus 로고
    • 2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients [1]
    • DOI 10.1038/sj.mp.4002023, PII 4002023
    • Zai, C. C.; De Luca, V.; Hwang, R. W.; Voineskos, A.; Muller, D. J.; Remington, G.; Kennedy, J. L. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol. Psychiatry, 2007, 12 (9), 794-795. (Pubitemid 47347796)
    • (2007) Molecular Psychiatry , vol.12 , Issue.9 , pp. 794-795
    • Zai, C.C.1    De Luca, V.2    Hwang, R.W.3    Voineskos, A.4    Muller, D.J.5    Remington, G.6    Kennedy, J.L.7
  • 59
    • 42349094914 scopus 로고    scopus 로고
    • Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: A meta-analysis of pharmacogenetic interactions
    • DOI 10.1038/sj.mp.4002142, PII 4002142
    • Bakker, P. R.; van Harten, P. N.; van Os, J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Molecular Psychiatry, 2008, 13 (5), 544-556. (Pubitemid 351556033)
    • (2008) Molecular Psychiatry , vol.13 , Issue.5 , pp. 544-556
    • Bakker, P.R.1    Van Harten, P.N.2    Van Os, J.3
  • 60
    • 75749148791 scopus 로고    scopus 로고
    • Pharmacogenetics of antipsychoticinduced side effects
    • Lencz, T.; Malhotra, A. K. Pharmacogenetics of antipsychoticinduced side effects. Dialogues Clin. Neurosci., 2009, 11 (4), 405-415
    • (2009) Dialogues Clin. Neurosci , vol.11 , Issue.4 , pp. 405-415
    • Lencz, T.1    Malhotra, A.K.2
  • 61
    • 0030903368 scopus 로고    scopus 로고
    • Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
    • Steen, V. M.; Lovlie, R.; MacEwan, T.; McCreadie, R. G. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry, 1997, 2 (2), 139-145. (Pubitemid 27166033)
    • (1997) Molecular Psychiatry , vol.2 , Issue.2 , pp. 139-145
    • Steen, V.M.1    Lovlie, R.2    MacEwan, T.3    McCreadie, R.G.4
  • 63
    • 0034894948 scopus 로고    scopus 로고
    • Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients
    • DOI 10.1159/000054924
    • Liao, D. L.; Yeh, Y. C.; Chen, H. M.; Chen, H.; Hong, C. J.; Tsai, S. J. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology, 2001, 44 (2), 95-98. (Pubitemid 32722308)
    • (2001) Neuropsychobiology , vol.44 , Issue.2 , pp. 95-98
    • Liao, D.-L.1    Yeh, Y.-C.2    Chen, H.-M.3    Chen, H.4    Hong, C.-J.5    Tsai, S.-J.6
  • 64
    • 0036342556 scopus 로고    scopus 로고
    • Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics
    • Woo, S. I.; Kim, J. W.; Rha, E.; Han, S. H.; Hahn, K. H.; Park, C. S.; Sohn, J. W. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. Psychiatry Clin. Neurosci., 2002, 56 (4), 469-474.
    • (2002) Psychiatry Clin. Neurosci , vol.56 , Issue.4 , pp. 469-474
    • Woo, S.I.1    Kim, J.W.2    Rha, E.3    Han, S.H.4    Hahn, K.H.5    Park, C.S.6    Sohn, J.W.7
  • 66
    • 73949158783 scopus 로고    scopus 로고
    • The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: A metaanalysis
    • Tsai, H. T.; North, K. E.; West, S. L.; Poole, C. The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a metaanalysis. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2010, 153B (1), 57-66.
    • (2010) Am. J. Med. Genet. B. Neuropsychiatr. Genet. , vol.153 B , Issue.1 , pp. 57-66
    • Tsai, H.T.1    North, K.E.2    West, S.L.3    Poole, C.4
  • 67
    • 34548671643 scopus 로고    scopus 로고
    • Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer's disease pharmacogenetics
    • DOI 10.2174/156720507781788846
    • Cacabelos, R.; Llovo, R.; Fraile, C.; Fernandez-Novoa, L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr. Alzheimer Res., 2007, 4 (4), 479-500. (Pubitemid 47416643)
    • (2007) Current Alzheimer Research , vol.4 , Issue.4 , pp. 479-500
    • Cacabelos, R.1    Llovo, R.2    Fraile, C.3    Fernandez-Novoa, L.4
  • 68
    • 84934444326 scopus 로고    scopus 로고
    • Pharmacogenomics in Alzheimer's disease
    • Cacabelos, R. Pharmacogenomics in Alzheimer's disease. Methods Mol. Biol., 2008, 448, 213-357.
    • (2008) Methods Mol. Biol , vol.448 , pp. 213-357
    • Cacabelos, R.1
  • 69
    • 33747888854 scopus 로고    scopus 로고
    • Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients
    • DOI 10.1007/s00228-006-0168-1
    • Varsaldi, F.; Miglio, G.; Scordo, M. G.; Dahl, M.-L.; Villa, L. M.; Biolcati, A.; Lombardi, G. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. European Journal of Clinical Pharmacology, 2006, 62 (9), 721-726. (Pubitemid 44289502)
    • (2006) European Journal of Clinical Pharmacology , vol.62 , Issue.9 , pp. 721-726
    • Varsaldi, F.1    Miglio, G.2    Scordo, M.G.3    Dahl, M.-L.4    Villa, L.M.5    Biolcati, A.6    Lombardi, G.7
  • 71
    • 79955693311 scopus 로고    scopus 로고
    • Association of CYP2D6*4 genetic polymorphism on the metabolism of Donepezil with Alzheimer's disease in Indian population
    • Subbiah, V.; Nirmal, S.; Tripathi, M.; Sagar, R. Association of CYP2D6*4 genetic polymorphism on the metabolism of Donepezil with Alzheimer's disease in Indian population. Annals of General Psychiatry, 2010, 9 (Suppl 1), S142.
    • (2010) Annals of General Psychiatry , vol.9 , Issue.SUPPL. 1
    • Subbiah, V.1    Nirmal, S.2    Tripathi, M.3    Sagar, R.4
  • 74
    • 37349000292 scopus 로고    scopus 로고
    • CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD
    • DOI 10.1016/j.euroneuro.2007.06.002, PII S0924977X07001265
    • Trzepacz, P. T.; Williams, D. W.; Feldman, P. D.; Wrishko, R. E.; Witcher, J. W.; Buitelaar, J. K. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur. Neuropsychopharmacol., 2008, 18 (2), 79-86. (Pubitemid 350296843)
    • (2008) European Neuropsychopharmacology , vol.18 , Issue.2 , pp. 79-86
    • Trzepacz, P.T.1    Williams, D.W.2    Feldman, P.D.3    Wrishko, R.E.4    Witcher, J.W.5    Buitelaar, J.K.6
  • 75
    • 33745049231 scopus 로고    scopus 로고
    • Severe liver injury after initiating therapy with atomoxetine in two children
    • DOI 10.1016/j.jpeds.2006.01.035, PII S002234760600014X
    • Lim, J. R.; Faught, P. R.; Chalasani, N. P.; Molleston, J. P. Severe liver injury after initiating therapy with atomoxetine in two children. J .Pediatr., 2006, 148 (6), 831-834. (Pubitemid 43870084)
    • (2006) Journal of Pediatrics , vol.148 , Issue.6 , pp. 831-834
    • Lim, J.R.1    Faught, P.R.2    Chalasani, N.P.3    Molleston, J.P.4
  • 76
    • 33846187164 scopus 로고    scopus 로고
    • Combined overdose of atomoxetine and methylphenidate in a cytochrome P450 2D6 poor metabolizer [15]
    • DOI 10.1097/JCP.0b013e31802d782c, PII 0000471420070200000032
    • Reimers, A.; Langsetmo, H. K. Combined overdose of atomoxetine and methylphenidate in a cytochrome P450 2D6 poor metabolizer. J. Clin. Psychopharmacol., 2007, 27 (1), 110-111. (Pubitemid 46105787)
    • (2007) Journal of Clinical Psychopharmacology , vol.27 , Issue.1 , pp. 110-111
    • Reimers, A.1    Langsetmo, H.K.2
  • 77
    • 77952899450 scopus 로고    scopus 로고
    • Role of Tetrabenazine for Huntington's Disease-Associated Chorea
    • Poon, L. H.; Kang, G. A.; Lee, A. J. Role of Tetrabenazine for Huntington's Disease-Associated Chorea. Annals of Pharmacotherapy, 2010, 44 (6), 1080-1089.
    • (2010) Annals of Pharmacotherapy , vol.44 , Issue.6 , pp. 1080-1089
    • Poon, L.H.1    Kang, G.A.2    Lee, A.J.3
  • 78
    • 0031029072 scopus 로고    scopus 로고
    • Long-term effects of tetrabenazine in hyperkinetic movement disorders
    • Jankovic, J.; Beach, J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology, 1997, 48 (2), 358-362. (Pubitemid 27087603)
    • (1997) Neurology , vol.48 , Issue.2 , pp. 358-362
    • Jankovic, J.1    Beach, J.2
  • 79
    • 34948839971 scopus 로고    scopus 로고
    • HLA-B*1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome
    • Yang, C. W.; Hung, S. I.; Juo, C. G.; Lin, Y. P.; Fang, W. H.; Lu, I. H.; Chen, S. T.; Chen, Y. T. HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J. Allergy Clin. Immunol., 2007, 120 (4), 870-877.
    • (2007) J. Allergy Clin. Immunol , vol.120 , Issue.4 , pp. 870-877
    • Yang, C.W.1    Hung, S.I.2    Juo, C.G.3    Lin, Y.P.4    Fang, W.H.5    Lu, I.H.6    Chen, S.T.7    Chen, Y.T.8
  • 87
    • 34248589506 scopus 로고    scopus 로고
    • Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese
    • DOI 10.1111/j.1528-1167.2007.01022.x
    • Man, C. B.; Kwan, P.; Baum, L.; Yu, E.; Lau, K. M.; Cheng, A. S.; Ng, M. H. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia, 2007, 48 (5), 1015-1018. (Pubitemid 46763406)
    • (2007) Epilepsia , vol.48 , Issue.5 , pp. 1015-1018
    • Man, C.B.L.1    Kwan, P.2    Baum, L.3    Yu, E.4    Lau, K.M.5    Cheng, A.S.H.6    Ng, M.H.L.7
  • 88
    • 67649687833 scopus 로고    scopus 로고
    • Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype
    • Chen, Y. C.; Chu, C. Y.; Hsiao, C. H. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. J. Eur. Acad. Dermatol. Venereol., 2009, 23 (6), 702-703.
    • (2009) J. Eur. Acad. Dermatol. Venereol , vol.23 , Issue.6 , pp. 702-703
    • Chen, Y.C.1    Chu, C.Y.2    Hsiao, C.H.3
  • 89
    • 78651293949 scopus 로고    scopus 로고
    • Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population
    • An, D. M.; Wu, X. T.; Hu, F. Y.; Yan, B.; Stefan, H.; Zhou, D. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population. Epilepsy Res., 2010, 92 (2-3), 226-230.
    • (2010) Epilepsy Res. , vol.92 , Issue.2-3 , pp. 226-230
    • An, D.M.1    Wu, X.T.2    Hu, F.Y.3    Yan, B.4    Stefan, H.5    Zhou, D.6
  • 90
    • 77949600882 scopus 로고    scopus 로고
    • Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese
    • Hung, S. I.; Chung, W. H.; Liu, Z. S.; Chen, C. H.; Hsih, M. S.; Hui, R. C.; Chu, C. Y.; Chen, Y. T. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics, 2010, 11 (3), 349-356.
    • (2010) Pharmacogenomics , vol.11 , Issue.3 , pp. 349-356
    • Hung, S.I.1    Chung, W.H.2    Liu, Z.S.3    Chen, C.H.4    Hsih, M.S.5    Hui, R.C.6    Chu, C.Y.7    Chen, Y.T.8
  • 91
    • 65249085648 scopus 로고    scopus 로고
    • Oxcarbazepineinduced Stevens-Johnson syndrome: A case report
    • Lin, L. C.; Lai, P. C.; Yang, S. F.; Yang, R. C. Oxcarbazepineinduced Stevens-Johnson syndrome: a case report. Kaohsiung J. Med. Sci., 2009, 25 (2), 82-86.
    • (2009) Kaohsiung J. Med. Sci , vol.25 , Issue.2 , pp. 82-86
    • Lin, L.C.1    Lai, P.C.2    Yang, S.F.3    Yang, R.C.4
  • 95
    • 0035217171 scopus 로고    scopus 로고
    • Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin
    • DOI 10.1097/00008571-200112000-00008
    • Kidd, R. S.; Curry, T. B.; Gallagher, S.; Edeki, T.; Blaisdell, J.; Goldstein, J. A. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics, 2001, 11 (9), 803-808. (Pubitemid 33151515)
    • (2001) Pharmacogenetics , vol.11 , Issue.9 , pp. 803-808
    • Kidd, R.S.1    Curry, T.B.2    Gallagher, S.3    Edeki, T.4    Blaisdell, J.5    Goldstein, J.A.6
  • 96
    • 0032891790 scopus 로고    scopus 로고
    • Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9(*)3 allele
    • Kidd, R. S.; Straughn, A. B.; Meyer, M. C.; Blaisdell, J.; Goldstein, J. A.; Dalton, J. T. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics, 1999, 9 (1), 71-80. (Pubitemid 29176726)
    • (1999) Pharmacogenetics , vol.9 , Issue.1 , pp. 71-80
    • Kidd, R.S.1    Straughn, A.B.2    Meyer, M.C.3    Blaisdell, J.4    Goldstein, J.A.5    Dalton, J.T.6
  • 99
    • 0034978572 scopus 로고    scopus 로고
    • The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement
    • DOI 10.1097/00008571-200106000-00002
    • van der Weide, J.; Steijns, L. S.; van Weelden, M. J.; de Haan, K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics, 2001, 11 (4), 287-291. (Pubitemid 32537401)
    • (2001) Pharmacogenetics , vol.11 , Issue.4 , pp. 287-291
    • Van der Weide, J.1    Steijns, L.S.W.2    Van Weelden, M.J.M.3    De Haan, K.4
  • 100
    • 2942560855 scopus 로고    scopus 로고
    • 450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions
    • DOI 10.1007/s00228-004-0753-0
    • Lee, A. Y.; Kim, M. J.; Chey, W. Y.; Choi, J.; Kim, B. G. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoininduced cutaneous adverse drug reactions. Eur. J. Clin. Pharmacol., 2004, 60 (3), 155-159. (Pubitemid 38757125)
    • (2004) European Journal of Clinical Pharmacology , vol.60 , Issue.3 , pp. 155-159
    • Lee, A.-Y.1    Kim, M.-J.2    Chey, W.-Y.3    Choi, J.4    Kim, B.-G.5
  • 101
    • 66649121223 scopus 로고    scopus 로고
    • Phenytoin Toxicity Due to Genetic Polymorphism
    • McCluggage, L. K.; Voils, S. A.; Bullock, M. R. Phenytoin Toxicity Due to Genetic Polymorphism. Neurocritical Care, 2008, 10 (2), 222-224.
    • (2008) Neurocritical Care , vol.10 , Issue.2 , pp. 222-224
    • McCluggage, L.K.1    Voils, S.A.2    Bullock, M.R.3
  • 102
    • 66849132349 scopus 로고    scopus 로고
    • CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant
    • McDonald, M. G.; Rieder, M. J.; Nakano, M.; Hsia, C. K.; Rettie, A. E. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol., 2009, 75 (6), 1337-1346.
    • (2009) Mol. Pharmacol , vol.75 , Issue.6 , pp. 1337-1346
    • McDonald, M.G.1    Rieder, M.J.2    Nakano, M.3    Hsia, C.K.4    Rettie, A.E.5
  • 103
    • 77951758756 scopus 로고    scopus 로고
    • Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing
    • Roper, N.; Storer, B.; Bona, R.; Fang, M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J. Mol. Diagn., 2010, 12 (3), 283-291.
    • (2010) J. Mol. Diagn. , vol.12 , Issue.3 , pp. 283-291
    • Roper, N.1    Storer, B.2    Bona, R.3    Fang, M.4
  • 104
    • 77953624552 scopus 로고    scopus 로고
    • Role of warfarin pharmacogenetic testing in clinical practice
    • Tan, G. M.; Wu, E.; Lam, Y. Y.; Yan, B. P. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics, 2010, 11 (3), 439-448.
    • (2010) Pharmacogenomics , vol.11 , Issue.3 , pp. 439-448
    • Tan, G.M.1    Wu, E.2    Lam, Y.Y.3    Yan, B.P.4
  • 105
    • 42449136621 scopus 로고    scopus 로고
    • Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: Comparison with other equations
    • DOI 10.2217/14622416.9.2.169
    • Wu, A. H.; Wang, P.; Smith, A.; Haller, C.; Drake, K.; Linder, M.; Valdes, R., Jr. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics, 2008, 9 (2), 169-178. (Pubitemid 351566941)
    • (2008) Pharmacogenomics , vol.9 , Issue.2 , pp. 169-178
    • Wu, A.H.B.1    Wang, P.2    Smith, A.3    Haller, C.4    Drake, K.5    Linder, M.6    Valdes Jr., R.7
  • 106
    • 33748787999 scopus 로고    scopus 로고
    • Pharmacogenetics, drug-metabolizing enzymes, and clinical practice
    • DOI 10.1124/pr.58.3.6
    • Gardiner, S. J.; Begg, E. J. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev., 2006, 58 (3), 521-590. (Pubitemid 44403684)
    • (2006) Pharmacological Reviews , vol.58 , Issue.3 , pp. 521-590
    • Gardiner, S.J.1    Begg, E.J.2
  • 110
    • 34347403221 scopus 로고    scopus 로고
    • Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes
    • DOI 10.1373/clinchem.2006.078139
    • Zhu, Y.; Shennan, M.; Reynolds, K. K.; Johnson, N. A.; Herrnberger, M. R.; Valdes, R., Jr.; Linder, M. W. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chem., 2007, 53 (7), 1199-1205. (Pubitemid 47020974)
    • (2007) Clinical Chemistry , vol.53 , Issue.7 , pp. 1199-1205
    • Zhu, Y.1    Shennan, M.2    Reynolds, K.K.3    Johnson, N.A.4    Herrnberger, M.R.5    Valdes Jr., R.6    Linder, M.W.7
  • 111
    • 23044440450 scopus 로고    scopus 로고
    • The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen
    • DOI 10.1182/blood-2005-03-1108
    • Sconce, E. A.; Khan, T. I.; Wynne, H. A.; Avery, P.; Monkhouse, L.; King, B. P.; Wood, P.; Kesteven, P.; Daly, A. K.; Kamali, F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 2005, 106 (7), 2329-2333. (Pubitemid 41510803)
    • (2005) Blood , vol.106 , Issue.7 , pp. 2329-2333
    • Sconce, E.A.1    Khan, T.I.2    Wynne, H.A.3    Avery, P.4    Monkhouse, L.5    King, B.P.6    Wood, P.7    Kesteven, P.8    Daly, A.K.9    Kamali, F.10
  • 113
    • 33746287448 scopus 로고    scopus 로고
    • Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with Ximelagatran
    • DOI 10.1080/10915810600683143, PII M78T5084531P3NN0
    • Harenberg, J.; Jorg, I.; Weiss, C. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. Int. J. Toxicol., 2006, 25 (3), 165-169. (Pubitemid 44105293)
    • (2006) International Journal of Toxicology , vol.25 , Issue.3 , pp. 165-169
    • Harenberg, J.1    Jorg, I.2    Weiss, C.3
  • 114
    • 65449158776 scopus 로고    scopus 로고
    • Clopidogrel resistance: Pharmacokinetic or pharmacogenetic?
    • Ford, N. F. Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J. Clin. Pharmacol., 2009, 49 (5), 506-512.
    • (2009) J. Clin. Pharmacol , vol.49 , Issue.5 , pp. 506-512
    • Ford, N.F.1
  • 117
    • 33749339075 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
    • DOI 10.1182/blood-2006-04-013052
    • Hulot, J. S.; Bura, A.; Villard, E.; Azizi, M.; Remones, V.; Goyenvalle, C.; Aiach, M.; Lechat, P.; Gaussem, P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 2006, 108 (7), 2244-2247. (Pubitemid 44497506)
    • (2006) Blood , vol.108 , Issue.7 , pp. 2244-2247
    • Hulot, J.-S.1    Bura, A.2    Villard, E.3    Azizi, M.4    Remones, V.5    Goyenvalle, C.6    Aiach, M.7    Lechat, P.8    Gaussem, P.9
  • 121
    • 69249137029 scopus 로고    scopus 로고
    • Biological determinants of endocrine resistance in breast cancer
    • Musgrove, E. A.; Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer, 2009, 9 (9), 631-643.
    • (2009) Nat. Rev. Cancer , vol.9 , Issue.9 , pp. 631-643
    • Musgrove, E.A.1    Sutherland, R.L.2
  • 122
    • 79951901358 scopus 로고    scopus 로고
    • Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen
    • author reply e586
    • Ferraldeschi, R.; Howell, S. J.; Thompson, A. M.; Newman, W. G. Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen. J. Clin. Oncol., 2010, 28 (29), e584-5; author reply e586.
    • (2010) J. Clin. Oncol. , vol.28 , Issue.29
    • Ferraldeschi, R.1    Howell, S.J.2    Thompson, A.M.3    Newman, W.G.4
  • 123
    • 77956242845 scopus 로고    scopus 로고
    • CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratification
    • Schroth, W.; Hamann, U.; Fasching, P. A.; Dauser, S.; Winter, S.; Eichelbaum, M.; Schwab, M.; Brauch, H. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin. Cancer Res, 2010, 16 (17), 4468-4477.
    • (2010) Clin. Cancer Res , vol.16 , Issue.17 , pp. 4468-4477
    • Schroth, W.1    Hamann, U.2    Fasching, P.A.3    Dauser, S.4    Winter, S.5    Eichelbaum, M.6    Schwab, M.7    Brauch, H.8
  • 125
    • 34247893863 scopus 로고    scopus 로고
    • Combined analysis of genetic polymorphisms in thymidylate synthase uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan
    • Martinez-Balibrea, E.; Manzano, J. L.; Martinez-Cardus, A.; Moran, T.; Cirauqui, B.; Catot, S.; Taron, M.; Abad, A. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. Oncol. Rep., 2007, 17 (3), 637-645.
    • (2007) Oncol. Rep , vol.17 , Issue.3 , pp. 637-645
    • Martinez-Balibrea, E.1    Manzano, J.L.2    Martinez-Cardus, A.3    Moran, T.4    Cirauqui, B.5    Catot, S.6    Taron, M.7    Abad, A.8
  • 128
    • 66349133649 scopus 로고    scopus 로고
    • Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan
    • Cecchin, E.; Innocenti, F.; D'Andrea, M.; Corona, G.; De Mattia, E.; Biason, P.; Buonadonna, A.; Toffoli, G. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol., 2009, 27 (15), 2457-2465.
    • (2009) J. Clin. Oncol , vol.27 , Issue.15 , pp. 2457-2465
    • Cecchin, E.1    Innocenti, F.2    D'Andrea, M.3    Corona, G.4    De Mattia, E.5    Biason, P.6    Buonadonna, A.7    Toffoli, G.8
  • 129
    • 42449139713 scopus 로고    scopus 로고
    • UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma
    • Liu, C. Y.; Chen, P. M.; Chiou, T. J.; Liu, J. H.; Lin, J. K.; Lin, T. C.; Chen, W. S.; Jiang, J. K.; Wang, H. S.; Wang, W. S. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer, 2008, 112 (9), 1932-1940.
    • (2008) Cancer , vol.112 , Issue.9 , pp. 1932-1940
    • Liu, C.Y.1    Chen, P.M.2    Chiou, T.J.3    Liu, J.H.4    Lin, J.K.5    Lin, T.C.6    Chen, W.S.7    Jiang, J.K.8    Wang, H.S.9    Wang, W.S.10
  • 131
    • 77953289476 scopus 로고    scopus 로고
    • Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis
    • Hu, Z. Y.; Yu, Q.; Zhao, Y. S. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur. J. Cancer, 2010, 46 (10), 1856-1865.
    • (2010) Eur. J. Cancer , vol.46 , Issue.10 , pp. 1856-1865
    • Hu, Z.Y.1    Yu, Q.2    Zhao, Y.S.3
  • 133
    • 78651083117 scopus 로고    scopus 로고
    • The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1
    • Fujita, K.; Sugiyama, M.; Akiyama, Y.; Ando, Y.; Sasaki, Y. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother. Pharmacol., 2011, 67 (1), 237-241.
    • (2011) Cancer Chemother. Pharmacol. , vol.67 , Issue.1 , pp. 237-241
    • Fujita, K.1    Sugiyama, M.2    Akiyama, Y.3    Ando, Y.4    Sasaki, Y.5
  • 134
    • 45849107951 scopus 로고    scopus 로고
    • Clinical pharmacology and pharmacogenetics of thiopurines
    • Sahasranaman, S.; Howard, D.; Roy, S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur. J. Clin. Pharmacol., 2008, 64 (8), 753-767.
    • (2008) Eur. J. Clin. Pharmacol , vol.64 , Issue.8 , pp. 753-767
    • Sahasranaman, S.1    Howard, D.2    Roy, S.3
  • 135
    • 55349099142 scopus 로고    scopus 로고
    • A personalized approach to cancer treatment: How biomarkers can help
    • Duffy, M. J.; Crown, J. A personalized approach to cancer treatment: how biomarkers can help. Clin. Chem., 2008, 54 (11), 1770-1779.
    • (2008) Clin. Chem , vol.54 , Issue.11 , pp. 1770-1779
    • Duffy, M.J.1    Crown, J.2
  • 138
    • 77953591482 scopus 로고    scopus 로고
    • Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia
    • Kapoor, G.; Sinha, R.; Naithani, R.; Chandgothia, M. Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia. Leuk. Res., 2010, 34 (8), 1023-1026.
    • (2010) Leuk. Res. , vol.34 , Issue.8 , pp. 1023-1026
    • Kapoor, G.1    Sinha, R.2    Naithani, R.3    Chandgothia, M.4
  • 139
    • 78650387508 scopus 로고    scopus 로고
    • Pazopanib in renal cell carcinoma
    • Ward, J. E.; Stadler, W. M. Pazopanib in renal cell carcinoma. Clin. Cancer Res., 2010, 16 (24), 5923-5927.
    • (2010) Clin. Cancer Res. , vol.16 , Issue.24 , pp. 5923-5927
    • Ward, J.E.1    Stadler, W.M.2
  • 141
    • 77958498524 scopus 로고    scopus 로고
    • An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors
    • Goh, B. C.; Reddy, N. J.; Dandamudi, U. B.; Laubscher, K. H.; Peckham, T.; Hodge, J. P.; Suttle, A. B.; Arumugham, T.; Xu, Y.; Xu, C. F.; Lager, J.; Dar, M. M.; Lewis, L. D. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin. Pharmacol. Ther., 2010, 88 (5), 652-659.
    • (2010) Clin. Pharmacol. Ther. , vol.88 , Issue.5 , pp. 652-659
    • Goh, B.C.1    Reddy, N.J.2    Dandamudi, U.B.3    Laubscher, K.H.4    Peckham, T.5    Hodge, J.P.6    Suttle, A.B.7    Arumugham, T.8    Xu, Y.9    Xu, C.F.10    Lager, J.11    Dar, M.M.12    Lewis, L.D.13
  • 142
    • 37449002083 scopus 로고    scopus 로고
    • Dihydropyrimidine Dehydrogenase Deficiency (Dpd) in Gi Malignancies: Experience of 4-Years
    • Saif, M. W.; Syrigos, K.; Mehra, R.; Mattison, L. K.; Diasio, R. B. Dihydropyrimidine Dehydrogenase Deficiency (Dpd) in Gi Malignancies: Experience of 4-Years. Pak. J. Med. Sci. Q., 2007, 23 (6), 832-839.
    • (2007) Pak. J. Med. Sci. Q , vol.23 , Issue.6 , pp. 832-839
    • Saif, M.W.1    Syrigos, K.2    Mehra, R.3    Mattison, L.K.4    Diasio, R.B.5
  • 143
    • 0023187085 scopus 로고
    • Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
    • Heggie, G. D.; Sommadossi, J. P.; Cross, D. S.; Huster, W. J.; Diasio, R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 1987, 47 (8), 2203-2206. (Pubitemid 17074634)
    • (1987) Cancer Research , vol.47 , Issue.8 , pp. 2203-2206
    • Heggie, G.D.1    Sommadossi, J.-P.2    Cross, D.S.3
  • 144
    • 1942453306 scopus 로고    scopus 로고
    • Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
    • DOI 10.1016/j.ejca.2003.12.004, PII S0959804903010694
    • van Kuilenburg, A. B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer, 2004, 40 (7), 939-950. (Pubitemid 38496249)
    • (2004) European Journal of Cancer , vol.40 , Issue.7 , pp. 939-950
    • Van Kuilenburg, A.B.P.1
  • 145
    • 14844303761 scopus 로고    scopus 로고
    • Capecitabine: A review
    • DOI 10.1016/j.clinthera.2005.01.005
    • Walko, C. M.; Lindley, C. Capecitabine: a review. Clin. Ther., 2005, 27 (1), 23-44. (Pubitemid 40347299)
    • (2005) Clinical Therapeutics , vol.27 , Issue.1 , pp. 23-44
    • Walko, C.M.1    Lindley, C.2
  • 146
    • 0034901306 scopus 로고    scopus 로고
    • Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency
    • van Kuilenburg, A. B.; Muller, E. W.; Haasjes, J.; Meinsma, R.; Zoetekouw, L.; Waterham, H. R.; Baas, F.; Richel, D. J.; vanGennip, A. H. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin. Cancer Res., 2001, 7 (5), 1149-1153. (Pubitemid 32708664)
    • (2001) Clinical Cancer Research , vol.7 , Issue.5 , pp. 1149-1153
    • Van Kuilenburg, A.B.P.1    Muller, E.W.2    Haasjes, J.3    Meinsma, R.4    Zoetekouw, L.5    Waterham, H.R.6    Baas, F.7    Richel, D.J.8    Van Gennip, A.H.9
  • 147
    • 0034808681 scopus 로고    scopus 로고
    • Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
    • Raida, M.; Schwabe, W.; Hausler, P.; Van Kuilenburg, A. B.; Van Gennip, A. H.; Behnke, D.; Hoffken, K. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin. Cancer Res., 2001, 7 (9), 2832-2839. (Pubitemid 32911393)
    • (2001) Clinical Cancer Research , vol.7 , Issue.9 , pp. 2832-2839
    • Raida, M.1    Schwabe, W.2    Hausler, P.3    Van Kuilenburg, A.B.P.4    Van Gennip, A.H.5    Behnke, D.6    Hoffken, K.7
  • 148
    • 0035074119 scopus 로고    scopus 로고
    • Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil
    • Yamaguchi, K.; Arai, Y.; Kanda, Y.; Akagi, K. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil. Jpn. J. Cancer Res, 2001, 92 (3), 337-342. (Pubitemid 32288297)
    • (2001) Japanese Journal of Cancer Research , vol.92 , Issue.3 , pp. 337-342
    • Yamaguchi, K.1    Arai, Y.2    Kanda, Y.3    Akagi, K.4
  • 149
    • 33749350447 scopus 로고    scopus 로고
    • Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians
    • DOI 10.1158/1078-0432.CCR-06-0747
    • Mattison, L. K.; Fourie, J.; Desmond, R. A.; Modak, A.; Saif, M. W.; Diasio, R. B. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin. Cancer Res., 2006, 12 (18), 5491-5495. (Pubitemid 44497265)
    • (2006) Clinical Cancer Research , vol.12 , Issue.18 , pp. 5491-5495
    • Mattison, L.K.1    Fourie, J.2    Desmond, R.A.3    Modak, A.4    Saif, M.W.5    Diasio, R.B.6
  • 150
    • 0036798968 scopus 로고    scopus 로고
    • High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity
    • DOI 10.1097/00008571-200210000-00007
    • Van Kuilenburg, A. B.; Meinsma, R.; Zoetekouw, L.; Van Gennip, A. H. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5- fluorouracil-associated toxicity. Pharmacogenetics, 2002, 12 (7), 555-558. (Pubitemid 35177085)
    • (2002) Pharmacogenetics , vol.12 , Issue.7 , pp. 555-558
    • Van Kuilenburg, A.B.P.1    Meinsma, R.2    Zoetekouw, L.3    Van Gennip, A.H.4
  • 151
    • 0034488052 scopus 로고    scopus 로고
    • Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
    • van Kuilenburg, A. B.; Haasjes, J.; Richel, D. J.; Zoetekouw, L.; Van Lenthe, H.; De Abreu, R. A.; Maring, J. G.; Vreken, P.; van Gennip, A. H. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5- fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res., 2000, 6 (12), 4705-4712. (Pubitemid 32110408)
    • (2000) Clinical Cancer Research , vol.6 , Issue.12 , pp. 4705-4712
    • Van Kuilenburg, A.B.P.1    Haasjes, J.2    Richel, D.J.3    Zoetekouw, L.4    Van Lenthe, H.5    De Abreu, R.A.6    Maring, J.G.7    Vreken, P.8    Van Gennip, A.H.9
  • 152
    • 0035712169 scopus 로고    scopus 로고
    • Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: The importance of analysis at diagnosis and significance of long-term follow-up
    • Papajik, T.; Jedlickova, K.; Kriegova, E.; Jarosova, M.; Raida, L.; Faber, E.; Hubacek, J.; Vondrakova, J.; Pikalova, Z.; Indrak, K. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up. Neoplasma, 2001, 48 (6), 501-505. (Pubitemid 34132567)
    • (2001) Neoplasma , vol.48 , Issue.6 , pp. 501-505
    • Papajik, T.1    Jedlickova, K.2    Kriegova, E.3    Jarosova, M.4    Raida, L.5    Faber, E.6    Hubacek, J.7    Vondrakova, J.8    Pikalova, Z.9    Indrak, K.10
  • 154
    • 33845219798 scopus 로고    scopus 로고
    • Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
    • DOI 10.1158/1535-7163.MCT-06-0327
    • Morel, A.; Boisdron-Celle, M.; Fey, L.; Soulie, P.; Craipeau, M. C.; Traore, S.; Gamelin, E. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther., 2006, 5 (11), 2895-2904. (Pubitemid 44849017)
    • (2006) Molecular Cancer Therapeutics , vol.5 , Issue.11 , pp. 2895-2904
    • Morel, A.1    Boisdron-Celle, M.2    Fey, L.3    Soulie, P.4    Craipeau, M.C.5    Traore, S.6    Gamelin, E.7
  • 156
    • 70649097093 scopus 로고    scopus 로고
    • Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas
    • Ragia, G.; Petridis, I.; Tavridou, A.; Christakidis, D.; Manolopoulos, V. G. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics, 2009, 10 (11), 1781-1787.
    • (2009) Pharmacogenomics , vol.10 , Issue.11 , pp. 1781-1787
    • Ragia, G.1    Petridis, I.2    Tavridou, A.3    Christakidis, D.4    Manolopoulos, V.G.5
  • 157
    • 72949108032 scopus 로고    scopus 로고
    • Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance
    • Wang, B.; Wang, J.; Huang, S. Q.; Su, H. H.; Zhou, S. F. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr. Drug Metab, 2009, 10 (7), 781-834.
    • (2009) Curr. Drug Metab , vol.10 , Issue.7 , pp. 781-834
    • Wang, B.1    Wang, J.2    Huang, S.Q.3    Su, H.H.4    Zhou, S.F.5
  • 158
    • 21744439005 scopus 로고    scopus 로고
    • Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents
    • DOI 10.1111/j.1365-2125.2005.02379.x
    • Holstein, A.; Plaschke, A.; Ptak, M.; Egberts, E. H.; El-Din, J.; Brockmoller, J.; Kirchheiner, J. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol., 2005, 60 (1), 103-106. (Pubitemid 40942788)
    • (2005) British Journal of Clinical Pharmacology , vol.60 , Issue.1 , pp. 103-106
    • Holstein, A.1    Plaschke, A.2    Ptak, M.3    Egberts, E.-H.4    El-Din, J.5    Brockmoller, J.6    Kirchheiner, J.7
  • 160
    • 44149110334 scopus 로고    scopus 로고
    • Allopurinol hypersensitivity syndrome: A preventable severe cutaneous adverse reaction?
    • Lee, H. Y.; Ariyasinghe, J. T.; Thirumoorthy, T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med. J., 2008, 49 (5), 384-387. (Pubitemid 351716706)
    • (2008) Singapore Medical Journal , vol.49 , Issue.5 , pp. 384-387
    • Lee, H.Y.1    Ariyasinghe, J.T.N.2    Thirumoorthy, T.3
  • 163
    • 34250888038 scopus 로고    scopus 로고
    • Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: What causes the diversity? [4]
    • DOI 10.1159/000102045
    • Dainichi, T.; Uchi, H.; Moroi, Y.; Furue, M. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology, 2007, 215 (1), 86-88. (Pubitemid 46976024)
    • (2007) Dermatology , vol.215 , Issue.1 , pp. 86-88
    • Dainichi, T.1    Uchi, H.2    Moroi, Y.3    Furue, M.4
  • 166
    • 65549125416 scopus 로고    scopus 로고
    • Genetic association studies to detect adverse drug reactions: Abacavir hypersensitivity as an example
    • Hughes, A. R.; Brothers, C. H.; Mosteller, M.; Spreen, W. R.; Burns, D. K. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example. Pharmacogenomics, 2009, 10 (2), 225-233.
    • (2009) Pharmacogenomics , vol.10 , Issue.2 , pp. 225-233
    • Hughes, A.R.1    Brothers, C.H.2    Mosteller, M.3    Spreen, W.R.4    Burns, D.K.5
  • 172
    • 20144380564 scopus 로고    scopus 로고
    • HLA-B*5701 typing by sequence-specific amplification: Validation and comparison with sequence-based typing
    • DOI 10.1111/j.1399-0039.2005.00401.x
    • Martin, A. M.; Nolan, D.; Mallal, S. HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens, 2005, 65 (6), 571-574. (Pubitemid 40776308)
    • (2005) Tissue Antigens , vol.65 , Issue.6 , pp. 571-574
    • Martin, A.M.1    Nolan, D.2    Mallal, S.3
  • 173
    • 36349024340 scopus 로고    scopus 로고
    • Prospective HLA-B*5701 screening and abacavir hypersensitivity: A single centre experience
    • DOI 10.1097/QAD.0b013e328273bc07, PII 0000203020071130000020
    • Waters, L. J.; Mandalia, S.; Gazzard, B.; Nelson, M. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. Aids, 2007, 21 (18), 2533-2534. (Pubitemid 350145186)
    • (2007) AIDS , vol.21 , Issue.18 , pp. 2533-2534
    • Waters, L.J.1    Mandalia, S.2    Gazzard, B.3    Nelson, M.4
  • 174
    • 0037006623 scopus 로고    scopus 로고
    • Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
    • DOI 10.1016/S0140-6736(02)07873-X
    • Mallal, S.; Nolan, D.; Witt, C.; Masel, G.; Martin, A. M.; Moore, C.; Sayer, D.; Castley, A.; Mamotte, C.; Maxwell, D.; James, I.; Christiansen, F. T. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet, 2002, 359 (9308), 727-732. (Pubitemid 34215071)
    • (2002) Lancet , vol.359 , Issue.9308 , pp. 727-732
    • Mallal, S.1    Nolan, D.2    Witt, C.3    Masel, G.4    Martin, A.M.5    Moore, C.6    Sayer, D.7    Castley, A.8    Mamotte, C.9    Maxwell, D.10    James, I.11    Christiansen, F.T.12
  • 175
    • 42449120613 scopus 로고    scopus 로고
    • Pharmacogenetic information derived from analysis of HLA alleles
    • DOI 10.2217/14622416.9.2.207
    • Gatanaga, H.; Honda, H.; Oka, S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics, 2008, 9 (2), 207-214. (Pubitemid 351566944)
    • (2008) Pharmacogenomics , vol.9 , Issue.2 , pp. 207-214
    • Gatanaga, H.1    Honda, H.2    Oka, S.3
  • 176
    • 17144377479 scopus 로고    scopus 로고
    • The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
    • van Leth, F.; Andrews, S.; Grinsztejn, B.; Wilkins, E.; Lazanas, M. K.; Lange, J. M.; Montaner, J. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. Aids, 2005, 19 (5), 463-471. (Pubitemid 40515849)
    • (2005) AIDS , vol.19 , Issue.5 , pp. 463-471
    • Van Leth, F.1    Andrews, S.2    Grinsztejn, B.3    Wilkins, E.4    Lazanas, M.K.5    Lange, J.M.A.6    Montaner, J.7
  • 177
    • 12144260460 scopus 로고    scopus 로고
    • Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts
    • Martin, A. M.; Nolan, D.; James, I.; Cameron, P.; Keller, J.; Moore, C.; Phillips, E.; Christiansen, F. T.; Mallal, S. Predisposition to nevirapine hypersensitivity associated with HLADRB1* 0101 and abrogated by low CD4 T-cell counts. Aids, 2005, 19 (1), 97-99. (Pubitemid 40111026)
    • (2005) AIDS , vol.19 , Issue.1 , pp. 97-99
    • Martin, A.M.1    Nolan, D.2    James, I.3    Cameron, P.4    Keller, J.5    Moore, C.6    Phillips, E.7    Christiansen, F.T.8    Mallal, S.9
  • 178
  • 180
    • 33845945094 scopus 로고    scopus 로고
    • HLA-Cw8 primarily associated with hypersensitivity to nevirapine [7]
    • DOI 10.1097/QAD.0b013e32801199d9, PII 0000203020070111000029
    • Gatanaga, H.; Yazaki, H.; Tanuma, J.; Honda, M.; Genka, I.; Teruya, K.; Tachikawa, N.; Kikuchi, Y.; Oka, S. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. Aids, 2007, 21 (2), 264-265. (Pubitemid 46036947)
    • (2007) AIDS , vol.21 , Issue.2 , pp. 264-265
    • Gatanaga, H.1    Yazaki, H.2    Tanuma, J.3    Honda, M.4    Genka, I.5    Teruya, K.6    Tachikawa, N.7    Kikuchi, Y.8    Oka, S.9
  • 182
    • 77952356637 scopus 로고    scopus 로고
    • Tuberculosis: What we don't know can, and does, hurt us
    • Russell, D. G.; Barry, C. E., 3rd; Flynn, J. L. Tuberculosis: what we don't know can, and does, hurt us. Science, 328 (5980), 852-6.
    • Science , vol.328 , Issue.5980 , pp. 852-6
    • Russell, D.G.1    Barry III, C.E.2    Flynn, L.J.3
  • 183
    • 0035432383 scopus 로고    scopus 로고
    • Mycobacterium tuberculosis: Here today, and here tomorrow
    • DOI 10.1038/35085034
    • Russell, D. G. Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. Mol. Cell Biol., 2001, 2 (8), 569-577. (Pubitemid 33674008)
    • (2001) Nature Reviews Molecular Cell Biology , vol.2 , Issue.8 , pp. 569-577
    • Russell, D.G.1
  • 184
    • 0036796798 scopus 로고    scopus 로고
    • Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment
    • DOI 10.1164/rccm.2108091
    • Sharma, S. K.; Balamurugan, A.; Saha, P. K.; Pandey, R. M.; Mehra, N. K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J.Respir. Crit. Care Med., 2002, 166 (7), 916-919. (Pubitemid 35193218)
    • (2002) American Journal of Respiratory and Critical Care Medicine , vol.166 , Issue.7 , pp. 916-919
    • Sharma, S.K.1    Balamurugan, A.2    Saha, P.K.3    Pandey, R.M.4    Mehra, N.K.5
  • 186
    • 0029079381 scopus 로고
    • Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians
    • Mehra, N. K.; Rajalingam, R.; Mitra, D. K.; Taneja, V.; Giphart, M. J. Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians. Int. J. Lepr. Other Mycobact. Dis., 1995, 63 (2), 241-248.
    • (1995) Int. J. Lepr. Other Mycobact. Dis , vol.63 , Issue.2 , pp. 241-248
    • Mehra, N.K.1    Rajalingam, R.2    Mitra, D.K.3    Taneja, V.4    Giphart, M.J.5
  • 188
    • 70449103049 scopus 로고    scopus 로고
    • Genetic association studies in drug-induced liver injury
    • Daly, A. K.; Day, C. P. Genetic association studies in drug-induced liver injury. Semin. Liver Dis., 2009, 29 (4), 400-411.
    • (2009) Semin. Liver Dis , vol.29 , Issue.4 , pp. 400-411
    • Daly, A.K.1    Day, C.P.2
  • 189
    • 78049469917 scopus 로고    scopus 로고
    • Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury
    • Donaldson, P. T.; Daly, A. K.; Henderson, J.; Graham, J.; Pirmohamed, M.; Bernal, W.; Day, C. P.; Aithal, G. P. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J. Hepatol., 53 (6), 1049-1053.
    • J. Hepatol. , vol.53 , Issue.6 , pp. 1049-1053
    • Donaldson, P.T.1    Daly, A.K.2    Henderson, J.3    Graham, J.4    Pirmohamed, M.5    Bernal, W.6    Day, C.P.7    Aithal, G.P.8
  • 190
    • 0033756344 scopus 로고    scopus 로고
    • Co-amoxiclav jaundice: Clinical and histological features and HLA class II association
    • O'Donohue, J.; Oien, K. A.; Donaldson, P.; Underhill, J.; Clare, M.; MacSween, R. N.; Mills, P. R. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut, 2000, 47 (5), 717-720.
    • (2000) Gut , vol.47 , Issue.5 , pp. 717-720
    • O'Donohue, J.1    Oien, K.A.2    Donaldson, P.3    Underhill, J.4    Clare, M.5    MacSween, R.N.6    Mills, P.R.7
  • 193
    • 0030902568 scopus 로고    scopus 로고
    • Stevens-Johnson syndrome induced by methazolamide treatment
    • Shirato, S.; Kagaya, F.; Suzuki, Y.; Joukou, S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch. Ophthalmol., 1997, 115 (4), 550-553. (Pubitemid 27172716)
    • (1997) Archives of Ophthalmology , vol.115 , Issue.4 , pp. 550-553
    • Shirato, S.1    Kagaya, F.2    Suzuki, Y.3    Jouhou, S.4
  • 194
    • 77952937737 scopus 로고    scopus 로고
    • HLA-B*5901 is strongly associated with methazolamideinduced Stevens-Johnson syndrome/toxic epidermal necrolysis
    • Kim, S. H.; Kim, M.; Lee, K. W.; Kang, H. R.; Park, H. W.; Jee, Y. K. HLA-B*5901 is strongly associated with methazolamideinduced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics, 2010, 11 (6), 879-884.
    • (2010) Pharmacogenomics , vol.11 , Issue.6 , pp. 879-884
    • Kim, S.H.1    Kim, M.2    Lee, K.W.3    Kang, H.R.4    Park, H.W.5    Jee, Y.K.6
  • 196
    • 1542407022 scopus 로고    scopus 로고
    • HLa association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population [3]
    • DOI 10.1016/j.jaci.2003.12.012
    • Choi, J. H.; Lee, K. W.; Oh, H. B.; Lee, K. J.; Suh, Y. J.; Park, C. S.; Park, H. S. HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population. J. Allergy Clin. Immunol., 2004, 113 (3), 562-564. (Pubitemid 38338966)
    • (2004) Journal of Allergy and Clinical Immunology , vol.113 , Issue.3 , pp. 562-564
    • Choi, J.H.1    Lee, K.W.2    Oh, H.B.3    Lee, K.J.4    Suh, Y.J.5    Park, C.S.6    Park, H.-S.7
  • 197
    • 17144408997 scopus 로고    scopus 로고
    • The human leucocyte antigen- DRB1*1302-DQB1*0609- DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria
    • Kim, S. H.; Choi, J. H.; Lee, K. W.; Shin, E. S.; Oh, H. B.; Suh, C. H.; Nahm, D. H.; Park, H. S. The human leucocyte antigen- DRB1*1302- DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin. Exp. Allergy, 2005, 35 (3), 339-44.
    • (2005) Clin. Exp. Allergy , vol.35 , Issue.3 , pp. 339-44
    • Kim, S.H.1    Choi, J.H.2    Lee, K.W.3    Shin, E.S.4    Oh, H.B.5    Suh, C.H.6    Nahm, D.H.7    Park, H.S.8
  • 198
    • 33645309625 scopus 로고    scopus 로고
    • Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males
    • Kim, S. H.; Oh, J. M.; Kim, Y. S.; Palmer, L. J.; Suh, C. H.; Nahm, D. H.; Park, H. S. Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin. Exp. Allergy, 2006, 36 (4), 433-439.
    • (2006) Clin. Exp. Allergy , vol.36 , Issue.4 , pp. 433-439
    • Kim, S.H.1    Oh, J.M.2    Kim, Y.S.3    Palmer, L.J.4    Suh, C.H.5    Nahm, D.H.6    Park, H.S.7
  • 199
    • 0033219772 scopus 로고    scopus 로고
    • Leukotriene C4 synthase: A candidate gene for the aspirin-intolerant asthmatic phenotype
    • Penrose, J. F.; Baldasaro, M. H. Leukotriene C4 synthase: a candidate gene for the aspirin-intolerant asthmatic phenotype. Allergy Asthma Proc., 1999, 20 (6), 353-360.
    • (1999) Allergy Asthma Proc , vol.20 , Issue.6 , pp. 353-360
    • Penrose, J.F.1    Baldasaro, M.H.2
  • 201
    • 31544442957 scopus 로고    scopus 로고
    • Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: Differing contributions of ALOX5 polymorphism in Korean population
    • Kim, S. H.; Choi, J. H.; Holloway, J. W.; Suh, C. H.; Nahm, D. H.; Ha, E. H.; Park, C. S.; Park, H. S. Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: differing contributions of ALOX5 polymorphism in Korean population. J. Korean Med. Sci., 2005, 20 (6), 926-931. (Pubitemid 43161853)
    • (2005) Journal of Korean Medical Science , vol.20 , Issue.6 , pp. 926-931
    • Kim, S.-H.1    Choi, J.-H.2    Holloway, J.W.3    Suh, C.-H.4    Nahm, D.-H.5    Ha, E.-H.6    Park, C.-S.7    Park, H.-S.8
  • 203
    • 33846850455 scopus 로고    scopus 로고
    • Significant association of FcεRIα promoter polymorphisms with aspirin-intolerant chronic urticaria
    • DOI 10.1016/j.jaci.2006.10.006, PII S0091674906021208
    • Bae, J. S.; Kim, S. H.; Ye, Y. M.; Yoon, H. J.; Suh, C. H.; Nahm, D. H.; Park, H. S. Significant association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria. J. Allergy Clin. Immunol., 2007, 119 (2), 449-456. (Pubitemid 46204803)
    • (2007) Journal of Allergy and Clinical Immunology , vol.119 , Issue.2 , pp. 449-456
    • Bae, J.-S.1    Kim, S.-H.2    Ye, Y.-M.3    Yoon, H.J.4    Suh, C.-H.5    Nahm, D.-H.6    Park, H.-S.7
  • 204
    • 47249123298 scopus 로고    scopus 로고
    • Association of three sets of high-affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin-intolerant asthma
    • Palikhe, N. S.; Kim, S. H.; Cho, B. Y.; Ye, Y. M.; Hur, G. Y.; Park, H. S. Association of three sets of high-affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin-intolerant asthma. Respir. Med., 2008, 102 (8), 1132-1139.
    • (2008) Respir. Med , vol.102 , Issue.8 , pp. 1132-1139
    • Palikhe, N.S.1    Kim, S.H.2    Cho, B.Y.3    Ye, Y.M.4    Hur, G.Y.5    Park, H.S.6
  • 205
    • 38049115502 scopus 로고    scopus 로고
    • Association of beta 2-adrenergic receptor polymorphism with the phenotype of aspirin-intolerant acute urticaria
    • Kim, H. A.; Ye, Y. M.; Kim, S. H.; Hur, G. Y.; Park, H. S. Association of beta 2-adrenergic receptor polymorphism with the phenotype of aspirin-intolerant acute urticaria. Yonsei Med. J., 2007, 48 (6), 1079-1081.
    • (2007) Yonsei Med. J , vol.48 , Issue.6 , pp. 1079-1081
    • Kim, H.A.1    Ye, Y.M.2    Kim, S.H.3    Hur, G.Y.4    Park, H.S.5
  • 206
    • 61349140008 scopus 로고    scopus 로고
    • Association of TNF-alpha promoter polymorphisms with aspirin-induced urticaria
    • Choi, J. H.; Kim, S. H.; Cho, B. Y.; Lee, S. K.; Suh, C. H.; Park, H. S. Association of TNF-alpha promoter polymorphisms with aspirin-induced urticaria. J. Clin. Pharm. Ther., 2009, 34 (2), 231-238.
    • (2009) J. Clin. Pharm. Ther , vol.34 , Issue.2 , pp. 231-238
    • Choi, J.H.1    Kim, S.H.2    Cho, B.Y.3    Lee, S.K.4    Suh, C.H.5    Park, H.S.6
  • 208
    • 76249091100 scopus 로고    scopus 로고
    • Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease
    • Palikhe, N. S.; Kim, S. H.; Cho, B. Y.; Ye, Y. M.; Choi, G. S.; Park, H. S. Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease. Allergy, 2010, 65 (3), 338-346.
    • (2010) Allergy , vol.65 , Issue.3 , pp. 338-346
    • Palikhe, N.S.1    Kim, S.H.2    Cho, B.Y.3    Ye, Y.M.4    Choi, G.S.5    Park, H.S.6
  • 210
    • 59349094942 scopus 로고    scopus 로고
    • Adenosine deaminase and adenosine receptor polymorphisms in aspirin-intolerant asthma
    • Kim, S. H.; Kim, Y. K.; Park, H. W.; Ye, Y. M.; Min, K. U.; Park, H. S. Adenosine deaminase and adenosine receptor polymorphisms in aspirin-intolerant asthma. Respir. Med., 2009, 103 (3), 356-363.
    • (2009) Respir. Med , vol.103 , Issue.3 , pp. 356-363
    • Kim, S.H.1    Kim, Y.K.2    Park, H.W.3    Ye, Y.M.4    Min, K.U.5    Park, H.S.6
  • 214
    • 77952908167 scopus 로고    scopus 로고
    • Personalized therapy in pain management: Where do we stand?
    • Stamer, U. M.; Zhang, L.; Stuber, F. Personalized therapy in pain management: where do we stand? Pharmacogenomics, 2010, 11 (6), 843-864.
    • (2010) Pharmacogenomics , vol.11 , Issue.6 , pp. 843-864
    • Stamer, U.M.1    Zhang, L.2    Stuber, F.3
  • 215
    • 77953517945 scopus 로고    scopus 로고
    • Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone
    • Gronlund, J.; Saari, T. I.; Hagelberg, N. M.; Neuvonen, P. J.; Olkkola, K. T.; Laine, K. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br. J. Clin. Pharmacol., 2010, 70 (1), 78-87.
    • (2010) Br. J. Clin. Pharmacol. , vol.70 , Issue.1 , pp. 78-87
    • Gronlund, J.1    Saari, T.I.2    Hagelberg, N.M.3    Neuvonen, P.J.4    Olkkola, K.T.5    Laine, K.6
  • 216
    • 34547644659 scopus 로고    scopus 로고
    • Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication
    • DOI 10.1038/sj.tpj.6500406, PII 6500406
    • Kirchheiner, J.; Schmidt, H.; Tzvetkov, M.; Keulen, J. T.; Lotsch, J.; Roots, I.; Brockmoller, J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J., 2007, 7 (4), 257-265. (Pubitemid 47202488)
    • (2007) Pharmacogenomics Journal , vol.7 , Issue.4 , pp. 257-265
    • Kirchheiner, J.1    Schmidt, H.2    Tzvetkov, M.3    Keulen, J.-T.4    Lotsch, J.5    Roots, I.6    Brockmoller, J.7
  • 217
    • 27544457008 scopus 로고    scopus 로고
    • Impact of CYP2C9 genotype on pharmacokinetics: Are all cyclooxygenase inhibitors the same?
    • DOI 10.1124/dmd.105.006452
    • Rodrigues, A. D. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab. Dispos., 2005, 33 (11), 1567-1575. (Pubitemid 41541940)
    • (2005) Drug Metabolism and Disposition , vol.33 , Issue.11 , pp. 1567-1575
    • Rodrigues, A.D.1
  • 218
    • 43049168656 scopus 로고    scopus 로고
    • Clinical use and pharmacological properties of selective COX-2 inhibitors
    • Shi, S.; Klotz, U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur. J. Clin. Pharmacol., 2008, 64 (3), 233-252.
    • (2008) Eur. J. Clin. Pharmacol , vol.64 , Issue.3 , pp. 233-252
    • Shi, S.1    Klotz, U.2
  • 219
    • 67649416267 scopus 로고    scopus 로고
    • Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
    • Agundez, J. A.; Garcia-Martin, E.; Martinez, C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin. Drug Metab. Toxicol., 2009, 5 (6), 607-620.
    • (2009) Expert Opin. Drug Metab. Toxicol , vol.5 , Issue.6 , pp. 607-620
    • Agundez, J.A.1    Garcia-Martin, E.2    Martinez, C.3
  • 221
  • 222
    • 0035653671 scopus 로고    scopus 로고
    • Genetics of susceptibility to human infectious disease
    • DOI 10.1038/35103577
    • Cooke, G. S.; Hill, A. V. Genetics of susceptibility to human infectious disease. Nat. Rev. Genet., 2001, 2 (12), 967-977. (Pubitemid 33691093)
    • (2001) Nature Reviews Genetics , vol.2 , Issue.12 , pp. 967-977
    • Cooke, G.S.1    Hill, A.V.S.2
  • 224
    • 79959503826 scopus 로고    scopus 로고
    • The International HapMap Project
    • The International HapMap Project. Nature, 2003, 426 (6968), 789-796.
    • (2003) Nature , vol.426 , Issue.6968 , pp. 789-796
  • 227
    • 27744516875 scopus 로고    scopus 로고
    • Diagnosis and management of G6PD deficiency
    • Frank, J. E. Diagnosis and management of G6PD deficiency. Am. Fam. Physician, 2005, 72 (7), 1277-1282. (Pubitemid 43104259)
    • (2005) American Family Physician , vol.72 , Issue.7 , pp. 1277-1282
    • Frank, J.E.1
  • 228
    • 84905027083 scopus 로고    scopus 로고
    • Accessed December 5 2010
    • Camptosar Full Prescribing Information. http://www.pfizer.com/files/ products/uspi-camptosar.pdf (Accessed December 5, 2010).
    • Camptosar Full Prescribing Information
  • 229
    • 76749143669 scopus 로고    scopus 로고
    • CYP2D6 polymorphisms and tamoxifen metabolism: Clinical relevance
    • Higgins, M. J.; Stearns, V. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr. Oncol. Rep., 2010, 12 (1), 7-15.
    • (2010) Curr. Oncol. Rep. , vol.12 , Issue.1 , pp. 7-15
    • Higgins, M.J.1    Stearns, V.2
  • 230
    • 77955638355 scopus 로고    scopus 로고
    • ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
    • Holmes Jr, D. R.; Dehmer, G. J.; Kaul, S.; Leifer, D.; O'Gara, P. T.; Stein, C. M. ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Journal of the American College of Cardiology, 2010, 56 (4), 321-341.
    • (2010) Journal of the American College of Cardiology , vol.56 , Issue.4 , pp. 321-341
    • Holmes Jr, D.R.1    Dehmer, G.J.2    Kaul, S.3    Leifer, D.4    O'Gara, P.T.5    Stein, C.M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.